Growth hormone treatment in Noonan syndrome: report of four cases who reached final height.

G Municchi, A M Pasquino, I Pucarelli, S Cianfarani, F Passeri
Author Information
  1. G Municchi: Pediatric Department, University La Sapienza, Rome, Italy.

Abstract

Final height of 4 patients with Noonan syndrome and short stature treated with growth hormone (GH) is reported. Four prepubertal girls (chronological age 12.3-15.1 years, bone age 11.0-11.5 years) were treated with recombinant human growth hormone (0.5 IU/kg/week s.c.) for at least 3 years. Stimulated GH secretion was normal, spontaneous nocturnal GH secretion was low in 1 patient. Final height, as standard deviation score according to Ranke-specific standards for Noonan syndrome, improved in 3 patients and 2 of the exceeded their corrected midparental height.

MeSH Term

Adolescent
Age Determination by Skeleton
Body Height
Child
Female
Growth Hormone
Humans
Noonan Syndrome
Recombinant Proteins

Chemicals

Recombinant Proteins
Growth Hormone